Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212): Complete Statistical AnalysisIndependent statistical analysis of Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration: Complete Statistical AnalysisIndependent statistical analysis of Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Multiple Doses of Saxagliptin (BMS-477118): Complete Statistical AnalysisIndependent statistical analysis of Study of Multiple Doses of Saxagliptin (BMS-477118): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00950599).
- Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery: Complete Statistical AnalysisIndependent statistical analysis of Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery:…
- Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus: Complete Statistical AnalysisIndependent statistical analysis of Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis: Complete Statistical AnalysisIndependent statistical analysis of Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Study of Nasal Insulin to Fight Forgetfulness – Device Study: Complete Statistical AnalysisIndependent statistical analysis of Study of Nasal Insulin to Fight Forgetfulness - Device Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03857321).
- Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292): Complete Statistical AnalysisIndependent statistical analysis of Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292): primary endpoint results, effect estimate…
- Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients: Complete Statistical AnalysisIndependent statistical analysis of Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Complete Statistical AnalysisIndependent statistical analysis of Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012): Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate…
- Study of Nivolumab for Advanced Cancers in India: Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab for Advanced Cancers in India: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03444766).
- Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064): Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers: Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139): Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate…
- Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer: Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of NKTR 255 in Combination With Cetuximab in Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study of NKTR 255 in Combination With Cetuximab in Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma: Complete Statistical AnalysisIndependent statistical analysis of Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment: Complete Statistical AnalysisIndependent statistical analysis of Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment: primary endpoint results, effect estimate with confidence interval, sample-size…
- Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.: Complete Statistical AnalysisIndependent statistical analysis of Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery…
- Study of OMNI Surgical System and iStent for Eyes With OAG (Trident): Complete Statistical AnalysisIndependent statistical analysis of Study of OMNI Surgical System and iStent for Eyes With OAG (Trident): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of Oral Edaravone in Healthy Adult Males: Complete Statistical AnalysisIndependent statistical analysis of Study of Oral Edaravone in Healthy Adult Males: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04481750).
- Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT): Complete Statistical AnalysisIndependent statistical analysis of Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT): primary endpoint results, effect estimate…
- Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function: Complete Statistical AnalysisIndependent statistical analysis of Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion: Complete Statistical AnalysisIndependent statistical analysis of Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002): Complete Statistical AnalysisIndependent statistical analysis of Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain: Complete Statistical AnalysisIndependent statistical analysis of Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain: primary endpoint results, effect estimate…
- Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Study of Panobinostat in Patients With Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study of Panobinostat in Patients With Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00985946).
- Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor: Complete Statistical AnalysisIndependent statistical analysis of Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.: Complete Statistical AnalysisIndependent statistical analysis of Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Study of Pazopanib and Ixabepilone in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study of Pazopanib and Ixabepilone in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01012362).
- Study of PEG-Intron for Plexiform Neurofibromas: Complete Statistical AnalysisIndependent statistical analysis of Study of PEG-Intron for Plexiform Neurofibromas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00396019).
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension: Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension: primary endpoint results, effect estimate with confidence…
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585): primary endpoint results, effect estimate with confidence interval,…
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355): primary endpoint results, effect estimate…